Editas Medicine, which is developing gene editing therapies based on CRISPR technology, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
The Cambridge, MA-based company, which was founded in 2013 and booked $1 million in sales for the 12 months ended September 30, 2015, plans to list on the Nasdaq under the symbol EDIT. Editas Medicine filed confidentially on 10/16/2015. Morgan Stanley, J.P. Morgan and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
